Cordenpharma, Viking Therapeutics form long-term partnership to provide key materials to make injectable and oral medications

Reuters

11 Mar

March 11 (Reuters) - Viking Therapeutics Inc ::
*CORDENPHARMA AND VIKING THERAPEUTICS SIGN LONG-TERM STRATEGIC PARTNERSHIP FOR INTEGRATED SUPPLY OF GLP-1 PEPTIDES, INJECTABLES AND ORAL FORMULATIONS
*CORDENPHARMA: PROVIDES LARGE-SCALE PEPTIDE MANUFACTURING FOR DUAL GLP-1/GIP RECEPTOR AGONIST DRUG SUBSTANCE OF VK2735
*CORDENPHARMA: TO PROVIDE FILL-FINISH FOR DRUG CANDIDATE'S SUBCUTANEOUS FORMULATION, ORAL SOLID DOSAGE MANUFACTURING FOR ORAL PEPTIDE FORMULATION

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 11-MAR-202512:00:08.22 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2518759740"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2518759740\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2518759740?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-11 21:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518759740","market":"us","top_or_hot":-1,"title":"Cordenpharma, Viking Therapeutics form long-term partnership to provide key materials to make injectable and oral medications","media":"Reuters","content":"<html><body>March 11 (Reuters) - Viking <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <vktx.o>::<br/>*CORDENPHARMA AND VIKING THERAPEUTICS SIGN LONG-TERM STRATEGIC PARTNERSHIP FOR INTEGRATED SUPPLY OF GLP-1 PEPTIDES, INJECTABLES AND ORAL FORMULATIONS<br/>*CORDENPHARMA: PROVIDES LARGE-SCALE PEPTIDE MANUFACTURING FOR DUAL GLP-1/GIP RECEPTOR AGONIST DRUG SUBSTANCE OF VK2735<br/>*CORDENPHARMA: TO PROVIDE FILL-FINISH FOR DRUG CANDIDATE'S SUBCUTANEOUS FORMULATION, ORAL SOLID DOSAGE MANUFACTURING FOR ORAL PEPTIDE FORMULATION<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 11-MAR-202512:00:08.22 GMT</vktx.o></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cordenpharma, Viking Therapeutics form long-term partnership to provide key materials to make injectable and oral medications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCordenpharma, Viking Therapeutics form long-term partnership to provide key materials to make injectable and oral medications\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-11 21:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>March 11 (Reuters) - Viking <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <vktx.o>::<br/>*CORDENPHARMA AND VIKING THERAPEUTICS SIGN LONG-TERM STRATEGIC PARTNERSHIP FOR INTEGRATED SUPPLY OF GLP-1 PEPTIDES, INJECTABLES AND ORAL FORMULATIONS<br/>*CORDENPHARMA: PROVIDES LARGE-SCALE PEPTIDE MANUFACTURING FOR DUAL GLP-1/GIP RECEPTOR AGONIST DRUG SUBSTANCE OF VK2735<br/>*CORDENPHARMA: TO PROVIDE FILL-FINISH FOR DRUG CANDIDATE'S SUBCUTANEOUS FORMULATION, ORAL SOLID DOSAGE MANUFACTURING FOR ORAL PEPTIDE FORMULATION<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 11-MAR-202512:00:08.22 GMT</vktx.o></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nRSD9cY8p4:1","article_id":"2518759740","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518759740","pubTimestamp":1741701172,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"March 11 (Reuters) - Viking Therapeutics Inc ::*CORDENPHARMA AND VIKING THERAPEUTICS SIGN LONG-TERM STRATEGIC PARTNERSHIP FOR INTEGRATED SUPPLY OF GLP-1 PEPTIDES, INJECTABLES AND ORAL FORMULATIONS*COR","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Cordenpharma与Viking Therapeutics建立长期合作伙伴关系，提供制造注射和口服药物的关键材料","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":0.9},"content_text":"March 11 (Reuters) - Viking Therapeutics Inc ::*CORDENPHARMA AND VIKING THERAPEUTICS SIGN LONG-TERM STRATEGIC PARTNERSHIP FOR INTEGRATED SUPPLY OF GLP-1 PEPTIDES, INJECTABLES AND ORAL FORMULATIONS*CORDENPHARMA: PROVIDES LARGE-SCALE PEPTIDE MANUFACTURING FOR DUAL GLP-1/GIP RECEPTOR AGONIST DRUG SUBSTANCE OF VK2735*CORDENPHARMA: TO PROVIDE FILL-FINISH FOR DRUG CANDIDATE'S SUBCUTANEOUS FORMULATION, ORAL SOLID DOSAGE MANUFACTURING FOR ORAL PEPTIDE FORMULATION  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 11-MAR-202512:00:08.22 GMT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}